Kenya’s Health Ministry Finds No Reported Autism Cases Related to Paracetamol Use

Kenya’s Pharmacy and Poisons Board (PPB) has confirmed that no cases of neurodevelopmental disorders linked to paracetamol use during pregnancy have been reported in the country.

In a statement released on Thursday, 2 October, PPB Chief Executive Officer Ahmed Mohamed said the board’s Pharmacovigilance Division has not received any reports associating the use of paracetamol with conditions such as autism spectrum disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD) in infants. He acknowledged that while some international studies have investigated possible links, the current evidence does not establish a causal relationship.

“Paracetamol is one of the most commonly used medicines both locally and globally,” Mohamed said. “Although certain studies have suggested potential associations with developmental conditions, there is no conclusive scientific evidence to confirm these claims.”

The PPB’s statement reflects the position of the World Health Organisation (WHO), which has also reviewed concerns about the safety of paracetamol during pregnancy. The WHO recently reaffirmed that available research does not demonstrate a consistent link between prenatal paracetamol use and neurodevelopmental disorders. 

The organisation emphasised that conditions such as autism are influenced by multiple factors, including genetics and early brain development. While the PPB maintains that paracetamol remains a safe and effective option for managing pain and fever during pregnancy, it advises that it should only be used under medical supervision. 

The clarification comes amid ongoing discussion on the use of over-the-counter medications during pregnancy and increased circulation of health claims through social media.